Maßnahmen zum peritonealen Langzeiterhalt

Tina Oberacker; Moritz Schanz; Jörg Latus; Severin Schricker

doi:10.1055/a-2247-2882

Nephrologie aktuell, Inhaltsverzeichnis

Nephrologie aktuell 2024; 28(04): 162-168
DOI: 10.1055/a-2247-2882

Schwerpunkt

Dialyse

Maßnahmen zum peritonealen Langzeiterhalt

Funktionserhalt der Peritonealmembran

Tina Oberacker

¹Dr. Margarete Fischer-Bosch Institut für Klinische Pharmakologie am Bosch Health Campus, Stuttgart

,

Moritz Schanz

²Abteilung für Allgemeine Innere Medizin und Nephrologie, Robert Bosch Krankenhaus, Stuttgart

,

Jörg Latus

²Abteilung für Allgemeine Innere Medizin und Nephrologie, Robert Bosch Krankenhaus, Stuttgart

,

Severin Schricker

²Abteilung für Allgemeine Innere Medizin und Nephrologie, Robert Bosch Krankenhaus, Stuttgart

› Institutsangaben

Abstract

ZUSAMMENFASSUNG

Die Zahl an Patienten, die auf ein Nierenersatzverfahren angewiesen sind, steigt stetig. Die Peritonealdialyse (PD) ist eine Methode zur Nierenersatztherapie, die hinsichtlich der Lebensqualität und Patientenautonomie häufig Vorteile gegenüber der Hämodialyse bieten kann. Allerdings ist die Langzeit-PD mit chronischen Veränderungen der Peritonealmembran wie Fibrose assoziiert, die den Teilchen- und Wassertransport erheblich beeinträchtigen und zum Ultrafiltrationsversagen führen können. Schlimmstenfalls treten schwere Komplikationen wie die enkapsulierende Peritonealsklerose (EPS) auf. In einigen Fällen kommt es sehr früh, d. h. nach etwa 5 Jahren oder weniger, zu Veränderungen, die zu einem Therapieversagen führen, sodass die PD beendet werden muss. Daher ist der möglichst lange Funktionserhalt der Membran von großer Bedeutung. In diesem Beitrag geben wir einen Überblick über Maßnahmen zum peritonealen Langzeiterhalt sowie einen Ausblick auf neue, potenzielle Therapeutika, die zu einer längeren Integrität der Peritonealmembran beitragen könnten.

Volltext

Referenzen

Literatur
1 Wakasugi M, Kazama JJ, Narita I. Anticipated increase in the number of patients who require dialysis treatment among the aging population of Japan. Ther Apher Dial 2015; 19: 201-206
2 Liyanage T, Ninomiya T, Jha V. et al Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015; 385: 1975-1982
3 Jung HY, Jeon Y, Park Y. et al Better Quality of Life of Peritoneal Dialysis compared to Hemodialysis over a Two-year Period after Dialysis Initiation. Sci Rep 2019; 09: 10266
4 Bustamante-Rojas L, D’Peña-Ardaillon F, Durán-Agüero S. et al [Health-related quality of life of patients on peritoneal dialysis]. Rev Med Chil 2021; 149: 1744-1750
5 Chuasuwan A, Pooripussarakul S, Thakkinstian A. et al Comparisons of quality of life between patients underwent peritoneal dialysis and hemodialysis: a systematic review and meta-analysis. Health Qual Life Outcomes 2020; 18: 191
6 Alwakeel JS, Alsuwaida A, Askar A. et al Outcome and complications in peritoneal dialysis patients: a five-year single center experience. Saudi J Kidney Dis Transpl 2011; 22: 245-251
7 Zarogiannis SG, Schmitt CP. Molecular Mechanisms of Peritoneal Membrane Pathophysiology. Biomolecules 2022: 12
8 Aroeira LS, Aguilera A, Sánchez-Tomero JA. et al Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol 2007; 18: 2004-2013
9 Blackburn SC, Stanton MP. Anatomy and physiology of the peritoneum. Semin Pediatr Surg 2014; 23: 326-330
10 Nevado J, Vallejo S, El-Assar M. et al Changes in the human peritoneal mesothelial cells during aging. Kidney Int 2006; 69: 313-322
11 Krediet RT. Aging of the Peritoneal Dialysis Membrane. Front Physiol 2022; 13: 885802
12 Williams JD, Craig KJ, Topley N. et al Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479
13 Braun N, Fritz P, Ulmer C. et al Histological Criteria for Encapsulating Peritoneal Sclerosis – A Standardized Approach. PLoS One 2012; 07: e48647
14 Rubin J, Herrera GA, Collins D. An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1991; 18: 97-102
15 Mateijsen MA, van der Wal AC, Hendriks PM. et al Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19: 517-525
16 Honda K, Oda H. Pathology of Encapsulating Peritoneal Sclerosis. Perit Dial Int 2005; 25 (Suppl. 04) S19-S29
17 Moinuddin Z, Summers A, Van Dellen D. et al Encapsulating peritoneal sclerosis—a rare but devastating peritoneal disease. Front Physiol 2015; 05: 470
18 Mistry CD, Gokal R. Alternative osmotic agents. Blood Purif 1989; 07: 109-114
19 Dousdampanis P, Musso CG, Trigka K. Icodextrin and peritoneal dialysis: advantages and new applications. Int Urol Nephrol 2018; 50: 495-500
20 Panzer SE, Teitelbaum I. Alternative dialysis strategies with icodextrin. Contrib Nephrol 2012; 178: 11-15
21 Williams JD, Topley N, Craig KJ. et al The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418
22 Cho Y, Johnson DW, Craig JC. et al Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev 2014: Cd007554
23 Htay H, Johnson DW, Wiggins KJ. et al Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev 2018; 10: Cd007554
24 Low S, Liew A. Peritoneal dialysis fluids. Semin Dial 2022; 37: 10-23
25 le Poole CY, van Ittersum FJ, Weijmer MC. et al Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study. Adv Perit Dial 2004; 20: 170-176
26 Kitterer D, Braun N, Alscher MD. et al The number of patients with severe encapsulating peritoneal sclerosis is decreasing in a large referral center in Germany. Int J Nephrol Renovasc Dis 2016; 09: 183-186
27 Peers E. Icodextrin plus glucose combinations for use in CAPD. Perit Dial Int 1997; 17 (Suppl. 02) S68-S69
28 Dousdampanis P, Trigka K, Bargman JM. Bimodal solutions or twice-daily icodextrin to enhance ultrafiltration in peritoneal dialysis patients. Int J Nephrol. 2013 2013 424915
29 Frampton JE, Plosker GL. Icodextrin: a review of its use in peritoneal dialysis. Drugs 2003; 63: 2079-2105
30 Cho Y, Johnson DW, Badve S. et al Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials. Nephrol Dial Transplant 2013; 28: 1899-1907
31 Savenkoff B, Flechon-Meibody F, Goffin É.. [Icodextrin: What arguments for and against its use as an osmotic agent in peritoneal dialysis]. Nephrol Ther 2018; 14: 201-206
32 de Fijter CWH, Stachowska-Pietka J, Waniewski J. et al High osmol gap hyponatremia caused by icodextrin: A case series report. Am J Nephrol 2024; 55: 202-205
33 Chaudhari H, Mahendrakar S, Akporotu A. et al Moderate hyperosmolar hyponatremia caused by excessive off-label use of icodextrin during peritoneal dialysis. Clinical nephrology Case studies 2023; 11: 61-65
34 de Alvaro F, Castro MJ, Dapena F. et al Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure. Adv Perit Dial 1993; 09: 56-61
35 Rodrigues A, Cabrita A, Maia P. et al Peritoneal rest may successfully recover ultrafiltration in patients who develop peritoneal hyperpermeability with time on continuous ambulatory peritoneal dialysis. Adv Perit Dial 2002; 18: 78-80
36 De Sousa E, Del Peso G, Alvarez L. et al Peritoneal resting with heparinized lavage reverses peritoneal type I membrane failure. A comparative study of the resting effects on normal membranes. Perit Dial Int 2014; 34: 698-705
37 Vychytil A, Herzog R, Probst P. et al A randomized controlled trial of alanyl-glutamine supplementation in peritoneal dialysis fluid to assess impact on biomarkers of peritoneal health. Kidney Int 2018; 94: 1227-1237
38 Kratochwill K, Boehm M, Herzog R. et al Addition of Alanyl-Glutamine to Dialysis Fluid Restores Peritoneal Cellular Stress Responses – A First-In-Man Trial. PLoS One 2016; 11: e0165045
39 Herzog R, Kuster L, Becker J. et al Functional and Transcriptomic Characterization of Peritoneal Immune-Modulation by Addition of Alanyl-Glutamine to Dialysis Fluid. Sci Rep 2017; 07: 6229
40 Herzog R, Boehm M, Unterwurzacher M. et al Effects of Alanyl-Glutamine Treatment on the Peritoneal Dialysis Effluent Proteome Reveal Pathomechanism-Associated Molecular Signatures. Mol Cell Proteomics 2018; 17: 516-532
41 Wiesenhofer FM, Herzog R, Boehm M. et al Targeted Metabolomic Profiling of Peritoneal Dialysis Effluents Shows Anti-oxidative Capacity of Alanyl-Glutamine. Frontiers Physiol 2018; 09: 1961
42 Herzog R, Bartosova M, Tarantino S. et al Peritoneal Dialysis Fluid Supplementation with Alanyl-Glutamine Attenuates Conventional Dialysis Fluid-Mediated Endothelial Cell Injury by Restoring Perturbed Cytoprotective Responses. Biomolecules 2020; 10: 1678
43 Bartosova M, Herzog R, Ridinger D. et al Alanyl-Glutamine Restores Tight Junction Organization after Disruption by a Conventional Peritoneal Dialysis Fluid. Biomolecules 2020; 10: 1178
44 Sacnun JM, Hoogenboom R, Eibensteiner F. et al Proteome-Wide Differential Effects of Peritoneal Dialysis Fluid Properties in an In Vitro Human Endothelial Cell Model. Int J Mol Sci 2022; 23: 8010
45 Ferrantelli E, Liappas G, Vila Cuenca M. et al The dipeptide alanyl-glutamine ameliorates peritoneal fibrosis and attenuates IL-17 dependent pathways during peritoneal dialysis. Kidney Int 2016; 89: 625-635
46 Schaefer B, Bartosova M, Macher-Goeppinger S. et al Neutral pH and low-glucose degradation product dialysis fluids induce major early alterations of the peritoneal membrane in children on peritoneal dialysis. Kidney Int 2018; 94: 419-429
47 Rottembourg J, Gahl GM, Poignet JL. et al Severe abdominal complications in patients undergoing continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc 1983; 20: 236-242
48 Habib SM, Betjes MG, Fieren MW. et al Management of encapsulating peritoneal sclerosis: a guideline on optimal and uniform treatment. Neth J Med 2011; 69: 500-507
49 Jagirdar RM, Bozikas A, Zarogiannis SG. et al Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options. Int J Mol Sci 2019; 20: 5765
50 Minetto Brabo A, Soares Do Carmo Reis N, Barretti P. et al A combination of corticosteroid, sirolimus, and intradialytic parenteral nutrition in encapsulating peritoneal sclerosis: Case report and literature review. Hemodial Int 2017; 21: 307-311
51 Farhat K, Stavenuiter AW, Beelen RH. et al Pharmacologic targets and peritoneal membrane remodeling. Perit Dial Int 2014; 34: 114-123
52 Mori Y, Matsuo S, Sutoh H. et al A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis 1997; 30: 275-278
53 Jung JY, Cho JT. A case of fulminant sclerosing peritonitis presented like acute culture-negative peritonitis and successfully treated with corticosteroid therapy. J Korean Med Sci 2013; 28: 620-623
54 Dejagere T, Evenepoel P, Claes K. et al Acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in a renal transplant recipient. Am J Kidney Dis 2005; 45: e33-e37
55 Kuriyama S, Tomonari H. Corticosteroid therapy in encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2001; 16: 1304-1305
56 Taguch K, Mitsuishi Y, Ito S. et al A Case of Encapsulating Peritoneal Sclerosis in a Patient Receiving Peritoneal Dialysis and Glucocorticoid Therapy. Intern Med 2023; 62: 3203-3207
57 Nakayama M, Miyazaki M, Honda K. et al Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions: the NEXT-PD study. Perit Dial Int 2014; 34: 766-774
58 Bhandari S, Wilkinson A, Sellars L. Sclerosing peritonitis: value of immunosuppression prior to surgery. Nephrol Dial Transplant 1994; 09: 436-437
59 Taguchi K, Mitsuishi Y, Ito S. et al Encapsulating Peritoneal Sclerosis in a Patient Receiving Peritoneal Dialysis and Glucocorticoid Therapy. Intern Med 2023; 62: 3203-3207
60 Guest S. Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences. Perit Dial Int 2009; 29: 252-255
61 Li Y, Xie QH, You HZ. et al Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial. Perit Dial Int 2012; 32: 507-515
62 Moustafellos P, Hadjianastassiou V, Roy D. et al Tamoxifen therapy in encapsulating sclerosing peritonitis in patients after kidney transplantation. Transplant Proc 2006; 38: 2913-2914
63 De Sousa-Amorim E, Del Peso G, Bajo MA. et al Can EPS development be avoided with early interventions? The potential role of tamoxifen – a single-center study. Perit Dial Int 2014; 34: 582-593
64 Summers AM, Clancy MJ, Syed F. et al Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int 2005; 68: 2381-2388
65 del Peso G, Bajo MA, Gil F. et al Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 2003; 19: 32-35
66 Allaria PM, Giangrande A, Gandini E. et al Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent?. J Nephrol 1999; 12: 395-397
67 Gupta S, Woodrow G. Successful treatment of fulminant encapsulating peritoneal sclerosis following fungal peritonitis with tamoxifen. Clin Nephrol 2007; 68: 125-129
68 Thirunavukarasu T, Saxena R, Anijeet H. et al Encapsulating peritoneal sclerosis presenting with recurrent ascites and tamoxifen: case reports and review of the literature. Ren Fail 2007; 29: 775-776
69 Mesquita M, Guillaume MP, Dratwa M. First use of tamoxifen in an HIV patient with encapsulating peritoneal sclerosis. Clin Drug Investig 2007; 27: 727-729
70 Mohamed AO, Kamar N, Nogier MB. et al Tamoxifen therapy in kidney-transplant patients presenting with severe encapsulating peritoneal sclerosis after treatment for acute humoral rejection. Exp Clin Transplant 2009; 07: 164-167
71 Korte MR, Fieren MW, Sampimon DE. et al Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. Nephrol Dial Transplant 2011; 26: 691-697
72 Coronel F, Cigarran S, Gomis A. et al Changes in peritoneal membrane permeability and proteinuria in patients on peritoneal dialysis after treatment with paricalcitol − a preliminary study. Clin Nephrol 2012; 78: 93-99
73 Zhang F, Zhang T, Yang S. et al Sacubitril-Valsartan Increases Ultrafiltration in Patients Undergoing Peritoneal Dialysis: A Short-Term Retrospective Self-Controlled Study. Front Med (Lausanne) 2022; 09: 831541
74 Kolesnyk I, Dekker FW, Noordzij M. et al Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients. Perit Dial Int 2007; 27: 446-453